Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The Delta SARS-CoV-2 variant is very infectious, and it is spreading quickly during this pandemic. In the study, we compared viral loads estimated by means of the Ct values emerging from RT-PCR swab tests in surging cases infected with the SARS-CoV-2 Delta variant in the fourth wave of COVID-19 with the three prior waves. The data comprised viral loads from positive cases detected within the UPMC health care system in Allegheny County, Pennsylvania. A total of 2059 upper airway samples were collected and tested for SARS-CoV-2 positive by RT-PCR during March 2020 to September 2021. We did not observe significant difference in viral load difference between the third (December 2020 to January 2021) and fourth (June 2021 to September 2021) waves; however, they had the higher viral load than the first (March 2020 to June 2020) and second waves (June 2020 to August 2020). We did find an age-related effect with the elderly presenting with lower viral loads, which was also seen in the earlier waves. However, the level of the viral loads in the fourth wave in the respect of the previous ones was not sufficiently increased to change our testing strategies by means of increased use of rapid antigen tests (RAT).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949736PMC
http://dx.doi.org/10.1177/11786361221087537DOI Listing

Publication Analysis

Top Keywords

viral loads
20
sars-cov-2 delta
8
delta variant
8
fourth wave
8
march 2020
8
september 2021
8
viral load
8
june 2020
8
loads
6
viral
6

Similar Publications

Activation of PD-1/PD-L1 immune checkpoint by Zika virus.

PLoS Pathog

September 2025

School of Biomedical Sciences, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China.

Zika virus (ZIKV) has emerged as a rising concern in global health in recent years. The role of PD-1/PD-L1 immune checkpoint in acute ZIKV infection remains to be understood. In this study we demonstrated the activation of PD-1/PD-L1 immune checkpoint by ZIKV.

View Article and Find Full Text PDF

Cytomegalovirus and Epstein-Barr Virus reactivation in steroid-refractory immune checkpoint inhibitor colitis.

J Infect Dev Ctries

August 2025

Gastroenterology Division, Internal Medicine Department, Sultan Qaboos Comprehensive Cancer and Research Center (SQCCCRC), University Medical City (UMC), Muscat, Sultanate of Oman.

Introduction: Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) reactivation are known complications in immunocompromised hosts, particularly transplant recipients. However, their occurrence and clinical implications in patients with solid tumors remain underexplored. The introduction of immune checkpoint inhibitors (ICIs) has transformed cancer therapy, but immune-related adverse events (irAEs), including colitis, are increasingly recognized.

View Article and Find Full Text PDF

The COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2 has highlighted the critical need for safe and effective vaccines. In this study, subunit nanovaccine formulations were developed using the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein encapsulated in polymeric nanoparticles composed of poly(ethylene glycol)-block-poly(ε-caprolactone) (PEG-PCL). Two surfactants, poly(vinyl alcohol) (PVA) and sodium cholate (SC), were evaluated during formulation via a modified water-in-oil-in-water (w/o/w) emulsion-solvent evaporation method.

View Article and Find Full Text PDF

Vertebrate animals and many small DNA and single-stranded RNA viruses that infect vertebrates have evolved to suppress genomic CpG dinucleotides. All organisms and most viruses additionally suppress UpA dinucleotides in protein-coding RNA. Synonymously recoding viral genomes to introduce CpG or UpA dinucleotides has emerged as an approach for viral attenuation and vaccine development.

View Article and Find Full Text PDF

Porcine reproductive and respiratory syndrome virus (PRRSV) imposes substantial economic losses on global swine production. While modified live vaccines remain the primary prevention tool, their efficacy is compromised by the genetic variability of PRRSV. This study developed a broadly neutralizing monoclonal antibody (mAb) that targets a conserved viral epitope as an alternative therapeutic strategy.

View Article and Find Full Text PDF